D Milonas1,2, A Laenen3, Z Venclovas4, L Jarusevicius5, G Devos6, S Joniau6. 1. Medical Academy, Department of Urology, Lithuanian University of Health Sciences, A. Mickeviciaus 9, 44307, Kaunas, Lithuania. daimantas.milonas@lsmuni.lt. 2. Department of Urology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. daimantas.milonas@lsmuni.lt. 3. Leuven Biostatistics and Statistical Bioinformatics Center, KU Leuven, Oude Markt 13, 3000, Leuven, Belgium. 4. Medical Academy, Department of Urology, Lithuanian University of Health Sciences, A. Mickeviciaus 9, 44307, Kaunas, Lithuania. 5. Medical Academy, Department of Oncology and Hematology, Lithuanian University of Health Sciences, A. Mickeviciaus 9, 44307, Kaunas, Lithuania. 6. Department of Urology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Abstract
BACKGROUND: Patients with prostate-specific antigen (PSA) persistence are at the increased risk of disease progression. The aim of our study was to evaluate the impact of early salvage therapy on oncological outcomes in patients with persistent PSA after radical prostatectomy (RP). METHODS: Within a single tertiary centre database, we identified men with persistent (≥ 0.1 ng/ml) versus undetectable (< 0.1 ng/ml) PSA 4-8 weeks after RP for high-risk prostate cancer (HRPCa). The cumulative incidence function was used to estimate cancer-specific survival (CSS) and clinical progression-free survival (CPFS). The Kaplan-Meier method was used to estimate overall survival (OS). The effects on oncological outcomes of salvage radiotherapy (SRT) ± androgen deprivation therapy (ADT) vs. ADT monotherapy were tested in the subgroup of patients with persistent PSA. RESULTS: Of 414 consecutive patients who underwent RP for HRPC, 125 (30.2%) had persistent PSA. Estimated 10-year CPFS, CSS and OS for men with persistent vs. undetectable PSA were 63.8% vs. 93.5%, 78.5% vs. 98.3% and 54% vs. 83.2% (all p < 0.0001), respectively. In men with persistent PSA, ADT alone was associated with higher risk (hazard ratio (HR) for worse CSS (HR 3.9, p = 0.005) and OS (HR 4.7, p < 0.0001) but not for CP (HR 1.6, p = 0.2) when compared with SRT ± ADT. CONCLUSION: In patients who underwent RP for HRPCa, persistent PSA was associated with poor oncological outcomes. Early SRT ± ADT resulted in significantly improved CSS and OS in men with persistent PSA comparing with early androgen deprivation monotherapy.
BACKGROUND: Patients with prostate-specific antigen (PSA) persistence are at the increased risk of disease progression. The aim of our study was to evaluate the impact of early salvage therapy on oncological outcomes in patients with persistent PSA after radical prostatectomy (RP). METHODS: Within a single tertiary centre database, we identified men with persistent (≥ 0.1 ng/ml) versus undetectable (< 0.1 ng/ml) PSA 4-8 weeks after RP for high-risk prostate cancer (HRPCa). The cumulative incidence function was used to estimate cancer-specific survival (CSS) and clinical progression-free survival (CPFS). The Kaplan-Meier method was used to estimate overall survival (OS). The effects on oncological outcomes of salvage radiotherapy (SRT) ± androgen deprivation therapy (ADT) vs. ADT monotherapy were tested in the subgroup of patients with persistent PSA. RESULTS: Of 414 consecutive patients who underwent RP for HRPC, 125 (30.2%) had persistent PSA. Estimated 10-year CPFS, CSS and OS for men with persistent vs. undetectable PSA were 63.8% vs. 93.5%, 78.5% vs. 98.3% and 54% vs. 83.2% (all p < 0.0001), respectively. In men with persistent PSA, ADT alone was associated with higher risk (hazard ratio (HR) for worse CSS (HR 3.9, p = 0.005) and OS (HR 4.7, p < 0.0001) but not for CP (HR 1.6, p = 0.2) when compared with SRT ± ADT. CONCLUSION: In patients who underwent RP for HRPCa, persistent PSA was associated with poor oncological outcomes. Early SRT ± ADT resulted in significantly improved CSS and OS in men with persistent PSA comparing with early androgen deprivation monotherapy.
Authors: François Audenet; Elise Seringe; Sarah J Drouin; Eva Comperat; Olivier Cussenot; Marc-Olivier Bitker; Morgan Rouprêt Journal: World J Urol Date: 2011-06-03 Impact factor: 4.226
Authors: Anup Kumar; Srinivas Samavedi; Vladimir Mouraviev; Anthony S Bates; Rafael F Coelho; Bernardo Rocco; Vipul R Patel Journal: J Robot Surg Date: 2016-05-31
Authors: Felix Preisser; Felix K H Chun; Raisa S Pompe; Alexander Heinze; Georg Salomon; Markus Graefen; Hartwig Huland; Derya Tilki Journal: Eur Urol Date: 2019-02-14 Impact factor: 20.096
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford Journal: Eur Urol Date: 2016-08-25 Impact factor: 20.096
Authors: Lorenzo Bianchi; Alessandro Nini; Marco Bianchi; Giorgio Gandaglia; Nicola Fossati; Nazareno Suardi; Marco Moschini; Paolo Dell'Oglio; Riccardo Schiavina; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2015-12-31 Impact factor: 20.096
Authors: Lisa Moris; Marcus G Cumberbatch; Thomas Van den Broeck; Giorgio Gandaglia; Nicola Fossati; Brian Kelly; Raj Pal; Erik Briers; Philip Cornford; Maria De Santis; Stefano Fanti; Silke Gillessen; Jeremy P Grummet; Ann M Henry; Thomas B L Lam; Michael Lardas; Matthew Liew; Malcolm D Mason; Muhammad Imran Omar; Olivier Rouvière; Ivo G Schoots; Derya Tilki; Roderick C N van den Bergh; Theodorus H van Der Kwast; Henk G van Der Poel; Peter-Paul M Willemse; Cathy Y Yuan; Badrinath Konety; Tanya Dorff; Suneil Jain; Nicolas Mottet; Thomas Wiegel Journal: Eur Urol Date: 2020-03-04 Impact factor: 20.096